210 filings
Page 6 of 11
8-K
xby8 8e3yf4a
13 Mar 20
Regulation FD Disclosure
9:06am
S-8
dcw72la 02y1g6wwir9
11 Mar 20
Registration of securities for employees
5:29pm
8-K
11xs3
11 Mar 20
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020
8:05am
8-K
063agmtqknw1avaypqos
2 Mar 20
Regulation FD Disclosure
3:48pm
8-K
az6 3h7wxk
7 Jan 20
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
8:05am
8-K
6e8hxi gw8svz9opbx3m
24 Dec 19
Departure of Directors or Certain Officers
12:00am
424B5
fpkjsz1g
12 Nov 19
Prospectus supplement for primary offering
8:02am
8-K
j7gfg2ts8vu
8 Nov 19
Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress
8:05am
8-K
nxabgd9sa4 fd
1 Nov 19
Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020
8:23am
424B5
oej502vtro
7 Oct 19
Prospectus supplement for primary offering
9:35pm
424B5
pic 9vv02owhx
7 Oct 19
Prospectus supplement for primary offering
9:33pm
8-K
h5b07i xy5rz59
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
424B5
54cta10 l68f
3 Oct 19
Prospectus supplement for primary offering
4:11pm
424B5
725d32g5dno
3 Oct 19
Prospectus supplement for primary offering
4:07pm
8-K
v4xcmdc 5h
23 Sep 19
Amendments to Articles of Incorporation or Bylaws
9:54pm
8-K
wxp91
23 Sep 19
Regulation FD Disclosure
8:00am
8-K
olpqx6i5fhf enb6oqyv
18 Sep 19
Unregistered Sales of Equity Securities
9:40pm
8-K
wbe929h3
12 Sep 19
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome
8:10am